Bone Abstracts

Recently, Y1 receptor (Y1R) has arisen as a potential regulator in the local control of bone turnover. BIBP3226 is a potent Y1R selective antagonist that was successfully used in in vitro studies showing a positive impact in the benefit of bone turnover, thus providing good perspectives for its use as a pharmacological tool for bone regeneration.However, BIBP3226 behaviour in a complex milieu such as the bone compartment is unknown. As drugs can...

Recent studies have demonstrated that the global or osteoblast-specific deletion of neuropeptide Y Y1 receptor (Y1R), as well as the pharmacological blockade of Y1R, leads to pronounced anabolic effects in bone metabolism. This suggests that anti-Y1R drug therapy might have clinical applications for the prevention/recovery of bone loss occurring in osteoporosis. Given the high fracture incidence in this target population, it remained...

see P194....

Neuropeptide Y Y1 receptor (Y1R) signalling has been shown to play a key role in bone homeostasis, emerging as a novel therapeutic target in bone diseases. Y1R knockout mice (Y1−/−) display a high-bone mass phenotype that has been mainly attributed to increased osteoblast activity. Nevertheless, the Y1R regulatory role on osteoclastogenesis and matrix resorption remains largely unknown. To clarify th...